Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.
- DOI
- 10.1155/2019/6402925
- Published
- 2019
- Container
- Journal of oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1155/2019/6402925,
title = {Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.},
author = {Qu D and Weygant N and Yao J and Chandrakesan P and Berry WL and May R and Pitts K and Husain S and Lightfoot S and Li M and Wang TC and An G and Clendenin C and Stanger BZ and Houchen CW},
year = {2019},
journal = {Journal of oncology},
doi = {10.1155/2019/6402925},
url = {https://doi.org/10.1155/2019/6402925}
}RIS
TY - JOUR TI - Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. AU - Qu D AU - Weygant N AU - Yao J AU - Chandrakesan P AU - Berry WL AU - May R AU - Pitts K AU - Husain S AU - Lightfoot S AU - Li M AU - Wang TC AU - An G AU - Clendenin C AU - Stanger BZ AU - Houchen CW PY - 2019 JO - Journal of oncology DO - 10.1155/2019/6402925 UR - https://doi.org/10.1155/2019/6402925 ER -
APA
D, Q., N, W., J, Y., P, C., WL, B., R, M., K, P., S, H., S, L., M, L., TC, W., G, A., C, C., BZ, S., & CW, H. (2019). Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.. Journal of oncology. https://doi.org/10.1155/2019/6402925
Source records
- pubmed · retrieved 2026-09-26T19:09:26.033Z